Home Tags Duocarmycin

Tag: duocarmycin

A Preclinical Profile of the Potential of BYON3521

A recent article, published in Molecular Cancer Therapeutics, an American Association for Cancer Research (AACR) journal, suggests that BYON3521, a next-generation antibody-drug conjugate being developed by clinical-stage Dutch...
Featured Image Courtesy: Byondis Biopharmaceuticals (previously Synthon Biopharmaceuticals, Nijmegen, The Netherlands.

Byondis and Medac Sign Collaboration and Supply Agreements for Trastuzumab Duocarmazine

Dutch clinical stage biopharmaceutical company Byondis has entered into a license, collaboration and supply agreement with Medac, a privately owned pharmaceutical company based in Germany. Byondis...

Second Generation HER2-antibody-drug conjugate Offers Best-in-Class Potential and Improved Therapeutic Index

In pre-clinical xenograft studies using patient-derived breast cancer and non-small-cell lung cancer material, Synthon Biopharmaceuticals, a subsidiary of specialty pharma company Synthon, has reported...